Drug news
Teva returns rights of laquinimod for multiple sclerosis to Active Biotech.
Teva Pharmaceutical Industries has decided not to pursue development of laquinimod, and has returned rights to the drug back to Swedish group Active Biotech. The decision follows the outcome of Phase II (LEGATO-HD) trial evaluating the safety and efficacy of laquinimod as a treatment in Huntington's disease, which failed to meet its primary endpoint of change from baseline after 12 months� treatment.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.